Stockholm3 Detects 400 Prostate Cancers vs 327 for PSA in 12,670-Men Trial
Updated
Updated · conexiant.com · Jun 27
Stockholm3 Detects 400 Prostate Cancers vs 327 for PSA in 12,670-Men Trial
3 articles · Updated · conexiant.com · Jun 27
Summary
In 12,670 Swedish men aged 50 to 74, Stockholm3 found 400 clinically significant prostate cancers within 2 years, versus 327 detected by PSA alone.
Sensitivity reached 90% for Stockholm3 against 74% for PSA, with 43 significant cancers missed versus 116; specificity stayed similar at 89% and 90%, respectively.
Per 1,000 men screened, Stockholm3 detected about 32 significant cancers versus 26 for PSA, while producing roughly comparable false positives—102 versus 95.
Decision-curve analysis favored Stockholm3 up to about a 25% biopsy-risk threshold, suggesting fewer missed cancers and unnecessary biopsies, though it also picked up more low-risk disease.
The secondary analysis used 2-year registry follow-up rather than universal baseline biopsy, and researchers said longer follow-up and cost data—European pricing is $550 to $750—are still needed.
Could a new blood test finally end the controversial era of PSA screening?
A new test detects 90% of aggressive prostate cancer. So what's the catch?
Stockholm3 Lowers Unnecessary Prostate Cancer Biopsies by 30% and Cuts Costs: A New Standard for Screening
Overview
Stockholm3 is an advanced blood-based test that marks a new era in prostate cancer screening. Unlike traditional PSA screening, which can lead to overdiagnosis of low-risk disease and unnecessary biopsies, Stockholm3 focuses on identifying clinically significant prostate cancer. This innovative approach improves the precision of screening, helping men receive the right care while avoiding unnecessary procedures. As a result, Stockholm3 not only enhances patient outcomes but also reduces the burden on healthcare resources, making prostate cancer screening more effective and efficient for both patients and healthcare systems.